HomeComparePAWAX vs ABBV

PAWAX vs ABBV: Dividend Comparison 2026

PAWAX yields 9.70% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $64.3K in total portfolio value· pulled ahead in Year 3
10 years
PAWAX
PAWAX
● Live price
9.70%
Share price
$67.67
Annual div
$6.57
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$38.0K
Annual income
$1,786.47
Full PAWAX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PAWAX vs ABBV

📍 ABBV pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPAWAXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PAWAX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PAWAX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAWAX
Annual income on $10K today (after 15% tax)
$824.77/yr
After 10yr DRIP, annual income (after tax)
$1,518.50/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $19,537.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAWAX + ABBV for your $10,000?

PAWAX: 50%ABBV: 50%
100% ABBV50/50100% PAWAX
Portfolio after 10yr
$70.2K
Annual income
$13,279.11/yr
Blended yield
18.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PAWAX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAWAX buys
0
ABBV buys
0
No recent congressional trades found for PAWAX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPAWAXABBV
Forward yield9.70%3.06%
Annual dividend / share$6.57$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$38.0K$102.3K
Annual income after 10y$1,786.47$24,771.77
Total dividends collected$13.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PAWAX vs ABBV ($10,000, DRIP)

YearPAWAX PortfolioPAWAX Income/yrABBV PortfolioABBV Income/yrGap
1$11,670$970.31$11,550$430.00+$120.00PAWAX
2$13,546$1,058.30$13,472$627.96+$74.00PAWAX
3← crossover$15,642$1,147.99$15,906$926.08$264.00ABBV
4$17,976$1,238.92$19,071$1,382.55$1.1KABBV
5$20,564$1,330.63$23,302$2,095.81$2.7KABBV
6$23,427$1,422.69$29,150$3,237.93$5.7KABBV
7$26,581$1,514.68$37,536$5,121.41$11.0KABBV
8$30,048$1,606.20$50,079$8,338.38$20.0KABBV
9$33,848$1,696.91$69,753$14,065.80$35.9KABBV
10$38,004$1,786.47$102,337$24,771.77$64.3KABBV

PAWAX vs ABBV: Complete Analysis 2026

PAWAXStock

The investment seeks to provide long-term capital growth by investing primarily in the common stocks of growth companies. The fund invests primarily (at least 65% of its total assets) in common stocks of U.S. companies operating in those sectors of the economy that, in T. Rowe Price&#39;s view, are the fastest growing or have the greatest growth potential. It may invest in foreign stocks in keeping with the fund&#39;s objective.

Full PAWAX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PAWAX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAWAX vs SCHDPAWAX vs JEPIPAWAX vs OPAWAX vs KOPAWAX vs MAINPAWAX vs JNJPAWAX vs MRKPAWAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.